의료진프로필

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

Cho, BC; Han, JY; Lee, KH; Lee, YG; Kim, DW; Min, YJ; Kim, SW; Cho, EK; Kim, JH; Lee, GW; Lee, SS; Lee, NM; Wang, JY; Park, H; Ahn, MJ

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION

Kato, T; Yang, JCH; Ahn, MJ; Sakai, H; Morise, M; Chen, YM; Han, JY; Yang, JJ; Zhao, J; Hsia, TC; Berghoff, K; Bruns, R; Vioix, H; Lang, S; Johne, A; Le, XN; Paik, PK

Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: A randomized clinical trial of biomarker targets

Chung, JW; Hwang, J; Kim, HJ; Seo, WK; Ahn, MJ; Saver, JL; Bang, OY

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma

Seiwert, TY; Wildsmith, S; Fayette, J; Harrington, K; Gillison, M; Ahn, MJ; Takahashi, S; Weiss, J; Machiels, JP; Baxi, S; Baker, V; Evans, B; Morsli, N; Walker, J; Real, K; L'Hernault, A; Psyrri, A

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Riely, GJ; Smit, EF; Ahn, MJ; Felip, E; Ramalingam, SS; Tsao, A; Johnson, M; Gelsomino, F; Esper, R; Nadal, E; Offin, M; Provencio, M; Clarke, J; Hussein, M; Otterson, GA; Dagogo-Jack, I; Goldman, JW; Morgensztern, D; Alcasid, A; Usari, T; Wissel, P; Wilner, K; Pathan, N; Tonkovyd, S; Johnson, BE

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Vokes, EE; Mornex, F; Sezer, A; Cheng, Y; Fang, J; Baz, DV; Cil, T; Adjei, AA; Ahn, MJ; Barlesi, F; Felip, E; Garon, EB; Audhuy, F; Ito, R; Sato, M; Eggleton, SP; Martin, CM; Reck, M; Robinson, CG; Paz-Ares, L

Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B

Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ

First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data

Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial

Kim, KH; Lim, SM; Ahn, HK; Lee, YG; Lee, KW; Ahn, MJ; Keam, B; Kim, HR; Lee, HW; An, HJ; Kim, JS

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

Lee, KH; Cho, BC; Ahn, MJ; Lee, YG; Lee, Y; Lee, JS; Kim, JH; Min, YJ; Lee, GW; Lee, SS; Lee, KH; Ko, YH; Shim, BY; Kim, SW; Shin, SW; Choi, JH; Kim, DW; Cho, EK; Park, KU; Kim, JS; Chun, SH; Wang, J; Choi, S; Kang, JH

Machine learning model for circulating tumor DNA detection in chronic obstructive pulmonary disease patients with lung cancer

Shin, SH; Cha, S; Lee, HY; Shin, SH; Kim, YJ; Park, D; Han, KY; Oh, YJ; Park, WY; Ahn, MJ; Kim, H; Won, HH; Park, HY

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Subbiah, V; Hu, M; Mansfield, AS; Taylor, MH; Schuler, M; Zhu, VW; Hadoux, J; Curigliano, G; Wirth, L; Gainor, JF; Alonso, G; Adkins, D; Godbert, Y; Ahn, MJ; Cassier, PA; Cho, BC; Lin, CC; Zalutskaya, A; Barata, T; Trask, P; Scalori, A; Bordogna, W; Heinzmann, S; Brose, MS

Prognostic Value of Radiomic Analysis Using Pre- and Post-Treatment 18F-FDG-PET/CT in Patients with Laryngeal Cancer and Hypopharyngeal Cancer

Choi, JH; Choi, JY; Woo, SK; Moon, JE; Lim, CH; Park, SB; Seo, S; Ahn, YC; Ahn, MJ; Moon, SH; Park, JM

Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)

Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study

Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial

Yang, JCH; Liu, GF; Lu, S; He, JX; Burotto, M; Ahn, MJ; Kim, DW; Liu, XQ; Zhao, YQ; Vincent, S; Yin, JN; Ma, X; Lin, HM; Popat, S

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Cho, BC; Lee, JS; Wu, YL; Cicin, I; Dols, MC; Ahn, MJ; Cuppens, K; Veillon, R; Nadal, E; Dias, JM; Martin, C; Reck, M; Garon, EB; Felip, E; Paz-Ares, L; Mornex, F; Vokes, EE; Adjei, AA; Robinson, C; Sato, M; Vugmeyster, Y; Machl, A; Audhuy, F; Chaudhary, S; Barlesi, F

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040) : Subgroup analysis by pattern of disease recurrence

Harrington, KJ; Cohen, EEW; Soulières, D; Dinis, J; Licitra, L; Ahn, MJ; Soria, A; Machiels, JP; Mach, N; Mehra, R; Burtness, B; Swaby, RF; Lin, J; Ge, J; Lerman, N; Le Tourneau, C

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Soo, RA; Cho, BC; Kim, JH; Ahn, MJ; Lee, KH; Zimina, A; Orlov, S; Bondarenko, I; Lee, YG; Lim, YN; Lee, SS; Lee, KH; Pang, YK; Fong, CH; Kang, JH; Lim, CS; Danchaivijitr, P; Kilickap, S; Yang, JCH; Arslan, C; Lee, HA; Park, SN; Cicin, I

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Goto, K; Goto, Y; Kubo, T; Ninomiya, K; Kim, SW; Planchard, D; Ahn, MJ; Smit, EF; de Langen, AJ; Pérol, M; Pons-Tostivint, E; Novello, S; Hayashi, H; Shimizu, J; Kim, DW; Kuo, CH; Yang, JCH; Pereira, K; Cheng, FC; Taguchi, A; Cheng, YK; Feng, WQ; Tsuchihashi, Z; Jänne, PA

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study

Ahn, MJ; Bondarenko, I; Kalinka, E; Cho, BC; Sugawara, S; Galffy, G; Shim, BY; Kislov, N; Nagarkar, R; Demedts, I; Gans, SJM; Oliva, DM; Stewart, R; Lai, ZW; Mann, H; Shi, XJ; Hussein, M

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Hanna, GJ; Ahn, MJ; Muzaffar, J; Keam, B; Bowles, DW; Wong, DJ; Ho, AL; Kim, SB; Worden, F; Yun, TK; Meng, XZ; Van Tornout, JM; Conlan, MG; Kang, H

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Razak, ARA; Wang, HM; Chang, JY; Ahn, MJ; Munster, P; Blumenschein, G Jr; Solomon, B; Lim, DWT; Hong, RL; Pfister, D; Saba, NF; Lee, SH; van Herpen, C; Quadt, C; Bootle, D; Blumenstein, L; Demanse, D; Delord, JP

Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

Ang, YLE; Zhao, XT; Reungwetwattana, T; Cho, BC; Liao, BC; Yeung, R; Loong, HH; Kim, DW; Yang, JCH; Lim, SM; Ahn, MJ; Lee, SH; Suwatanapongched, T; Kongchauy, K; Ou, QX; Yu, RY; Tai, BC; Goh, BC; Mok, TSK; Soo, RA

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Kim, H; Park, S; Jung, HA; Lee, SH; Park, K; Ahn, YC; Oh, D; Ahn, MJ

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Ahn, MJ; Cho, BC; Felip, E; Korantzis, I; Ohashi, K; Majem, M; Juan-Vidal, O; Handzhiev, S; Izumi, H; Lee, JS; Dziadziuszko, R; Wolf, J; Blackhall, F; Reck, M; Alvarez, JB; Hummel, HD; Dingemans, AMC; Sands, J; Akamatsu, H; Owonikoko, TK; Ramalingam, SS; Borghaei, H; Johnson, ML; Huang, S; Mukherjee, S; Minocha, M; Jiang, TY; Martinez, P; Anderson, ES; Paz-Ares, L

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301

Reungwetwattana, T; Cho, BC; Lee, KH; Pang, YK; Fong, CH; Kang, JH; Lee, YG; Sen Lim, C; Danchaivijitr, P; Lim, YN; Lee, YJ; How, SH; Geater, S; Lee, SS; Min, YJ; Kim, JH; Lee, JS; Lee, GW; Soo, RA; Lee, SY; Choi, S; Ahn, MJ

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing

Lim, TKH; Skoulidis, F; Kerr, KM; Ahn, MJ; Kapp, JR; Soares, FA; Yatabe, Y

Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma

Kim, DH; Lim, Y; Ock, CY; Park, G; Park, S; Song, H; Ma, MN; Mostafavi, M; Kang, EJ; Ahn, MJ; Lee, KW; Kwon, JH; Yang, YW; Choi, YH; Kim, MK; Ji, JH; Yun, TK; Kim, SB; Keam, B

Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer

Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

Prognostic Significance of Volumetric Parameters Based on FDG PET/CT in Patients with Lung Adenocarcinoma Undergoing Curative Surgery

Lee, H; Choi, YL; Kim, HK; Choi, YS; Kim, H; Ahn, MJ; Pyo, HR; Choi, JY

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301

Cho, BC; Ahn, MJ; Kang, JH; Soo, RA; Reungwetwattana, T; Yang, JCH; Cicin, I; Kim, DW; Wu, YL; Lu, S; Lee, KH; Pang, YK; Zimina, A; Fong, CH; Poddubskaya, E; Sezer, A; How, SH; Danchaivijitr, P; Kim, Y; Lim, Y; An, T; Lee, HA; Byun, HM; Zaric, B

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors A Phase 1a/1b Nonrandomized Controlled Trial

Kim, TW; Bedard, PL; Lorusso, P; Gordon, MS; Bendell, J; Oh, D; Ahn, MJ; Garralda, E; D'Angelo, SP; Desai, J; Hodi, FS; Wainberg, Z; Delord, JP; Cassier, PA; Cervantes, A; Gil-Martin, M; Wu, B; Patil, NS; Jin, Y; Hoang, T; Mendus, D; Wen, X; Meng, R; Cho, BC

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer

Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J

Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Gray, JE; Ahn, MJ; Oxnard, GR; Shepherd, FA; Imamura, F; Cheng, Y; Okamoto, I; Cho, BC; Lin, MC; Wu, YL; Majem, M; Gautschi, O; Boyer, M; Bulusu, KC; Markovets, A; Barrett, JC; Hodge, R; Mckeown, A; Hartmaier, RJ; Chmielecki, J; Papadimitrakopoulou, VA; Ramalingam, SS

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer

Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

Gutierrez, M; Lam, WS; Hellmann, MD; Gubens, MA; Aggarwal, C; Tan, DSW; Felip, E; Chiu, JWY; Lee, JS; Yang, JCH; Garon, EB; Finocchiaro, G; Ahn, MJ; Luft, A; Landers, GA; Basso, A; Ma, H; Kobie, J; Palcza, J; Cristescu, R; Fong, L; Snyder, A; Yuan, JD; Herbst, RS

Detection of Cancer Recurrence Using Systemic Inflammatory Markers and Machine Learning after Concurrent Chemoradiotherapy for Head and Neck Cancers

So, YK; Kim, Z; Cheong, TY; Chung, MJ; Baek, CH; Son, YI; Seok, J; Jung, YS; Ahn, MJ; Ahn, YC; Oh, D; Cho, BH; Chung, MK

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Riely, GJ; Smit, EF; Ahn, MJ; Felip, E; Ramalingam, SS; Tsao, A; Johnson, M; Gelsomino, F; Esper, R; Nadal, E; Offin, M; Provencio, M; Clarke, J; Hussain, M; Otterson, GA; Dagogo-Jack, I; Goldman, JW; Morgensztern, D; Alcasid, A; Usari, T; Wissel, P; Wilner, K; Pathan, N; Tonkovyd, S; Johnson, BE

Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Lee, DH; Kim, HR; Keam, B; Kato, K; Kuboki, Y; Gao, HY; Yovine, A; Robbins, SH; Ahn, MJ

A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer

Seo, S; Keam, B; Shin, SH; Chae, YS; Kim, TM; Park, LC; Hong, SB; Ahn, MJ; Kim, SB

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

Mazieres, J; Paik, PK; Garassino, MC; Le, XN; Sakai, H; Veillon, R; Smit, EF; Cortot, AB; Raskin, J; Viteri, S; Wu, YL; Yang, JCH; Ahn, MJ; Ma, R; Zhao, J; O'Brate, A; Berghoff, K; Bruns, R; Otto, G; Johne, A; Felip, E; Thomas, M

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer

Galffy, G; Lugowska, I; Poddubskaya, EV; Cho, BC; Ahn, MJ; Han, JY; Su, WC; Hauke, RJ; Dyar, SH; Lee, DH; Serwatowski, P; Estelles, DL; Holden, VR; Kim, YJ; Vladimirov, V; Horvath, Z; Ghose, A; Goldman, A; di Pietro, A; Wang, J; Murphy, DA; Alhadab, A; Laskov, M

Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity

Song, J; Jeong, BS; Kim, SW; Im, SB; Kim, S; Lai, CJ; Cho, W; Jung, JU; Ahn, MJ; Oh, BH; Ng, T

A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Lee, J; Park, S; Jung, HA; Lee, SH; Seo, S; Kim, SB; Kim, JW; Lee, KW; Kang, EJ; Kim, JW; Choi, YJ; Shim, BY; An, HJ; Park, LC; Shin, SH; Kim, JJ; Oh, SY; Kim, MK; Ahn, MJ

The prognostic value of radiomic features from pre- and post-treatment F-18-FDG PET imaging in patients with nasopharyngeal carcinoma

Kim, SJ; Choi, JY; Ahn, YC; Ahn, MJ; Moon, SH

Circulating Extracellular-Vesicle-Incorporated MicroRNAs as Potential Biomarkers for Ischemic Stroke in Patients With Cancer

Bang, OY; Kim, EH; Oh, MJ; Yoo, J; Oh, GS; Chung, JW; Seo, WK; Kim, GM; Ahn, MJ; Yang, SW; OASIS-CANC Study

EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

Radiomics Analysis of F-18-FDG PET/CT for Prognosis Prediction in Patients with Stage III Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiation Therapy Followed by Surgery

Yoo, J; Lee, JH; Cheon, M; Kim, H; Choi, YS; Pyo, H; Ahn, MJ; Choi, JY

Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells

Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW

Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance

Hwang, S; Hong, TH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Han, J; Ahn, YC; Pyo, H; Noh, JM; Lee, HY; Kim, HJ; Park, S; Ahn, MJ; Park, K; Lee, SH; Choi, YL; Kim, J

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Chan, ATC; Lee, VHF; Hong, RL; Ahn, MJ; Chong, WQ; Kim, SB; Ho, GF; Caguioa, PB; Ngamphaiboon, N; Ho, C; Aziz, MASA; Ng, QS; Yen, CJ; Soparattanapaisarn, N; Ngan, RKC; Kho, SK; Tiambeng, MLA; Yun, T; Sriuranpong, V; Algazi, AP; Cheng, A; Massarelli, E; Swaby, RF; Saraf, S; Yuan, J; Siu, LL

Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K

Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma

Hong, TH; Hwang, S; Choi, YL; Lee, GEH; Park, S; Ahn, MJ; Lee, Y; Jeon, YJ; Lee, J; Shin, S; Park, SY; Cho, JH; Choi, YS; Kim, J; Shim, YM; Cho, JH; Kim, HK

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia

Mitsudomi, T; Tan, D; Yang, JCH; Ahn, MJ; Batra, U; Cho, BC; Cornelio, G; Lim, T; Mok, T; Prabhash, K; Reungwetwattana, T; Ren, SX; Singh, N; Toyooka, S; Wu, YL; Yang, PC; Yatabe, Y

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment

Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Chmielecki, J; Mok, T; Wu, YL; Han, JY; Ahn, MJ; Ramalingam, SS; John, T; Okamoto, I; Yang, JCH; Shepherd, FA; Bulusu, KC; Laus, G; Collins, B; Barrett, JC; Hartmaier, RJ; Papadimitrakopoulou, V

Prognostic Significance of the Post-Treatment Neutrophil-to-Lymphocyte Ratio in Pharyngeal Cancers Treated with Concurrent Chemoradiotherapy

Yun, JM; Chung, MK; Baek, CH; Son, YI; Ahn, MJ; Oh, D; Kim, KW; So, YK

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Psyrri, A; Fayette, J; Harrington, K; Gillison, M; Ahn, MJ; Takahashi, S; Weiss, J; Machiels, JP; Baxi, S; Vasilyev, A; Karpenko, A; Dvorkin, M; Hsieh, CY; Thungappa, SC; Segura, PP; Vynnychenko, I; Haddad, R; Kasper, S; Mauz, PS; Baker, V; He, P; Evans, B; Wildsmith, S; Olsson, RF; Yovine, A; Kurland, JF; Morsli, N; Seiwert, TY

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)

Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis

Park, YJ; Im, Y; Kwon, OJ; Han, J; Ahn, MJ; Kim, J; Um, SW; Choi, JY

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Popat, S; Ahn, MJ; Ekman, S; Leighl, NB; Ramalingam, SS; Reungwetwattana, T; Siva, S; Tsuboi, M; Wu, YL; Yang, JCH

Osimertinib plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

Hartmaier, RJ; Markovets, AA; Ahn, MJ; Sequist, LV; Han, JY; Cho, BC; Yu, HA; Kim, SW; Yang, JCH; Lee, JS; Su, WC; Kowalski, DM; Orlov, S; Ren, S; Frewer, P; Ou, XL; Cross, DAE; Kurian, N; Cantarini, M; Janne, PA

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI

Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ

Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer

Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma

Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

Ahn, MJ; Kim, HR; Yang, JCH; Han, JY; Li, JYC; Hochmair, MJ; Chang, GC; Delmonte, A; Lee, KH; Campelo, RG; Gridelli, C; Spira, AI; Califano, R; Griesinger, F; Ghosh, S; Felip, E; Kim, DW; Liu, YY; Zhang, PK; Popat, S; Camidge, DR

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

Ou, SHI; Nishio, M; Ahn, MJ; Mok, T; Barlesi, F; Zhou, CC; Felip, E; de Marinis, F; Kim, SW; Perol, M; Liu, G; Migliorino, MR; Kim, DW; Novello, S; Bearz, A; Garrido, P; Mazieres, J; Morabito, A; Lin, HM; Yang, H; Niu, HF; Zhang, PK; Kim, ES

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

Ahn, MJ; Mendoza, MJL; Pavlakis, N; Kato, T; Soo, RA; Kim, DW; Liam, CK; Hsia, TC; Lee, CK; Reungwetwattana, T; Geater, S; Chan, OSH; Prasongsook, N; Solomon, BJ; Nguyen, TTH; Kozuki, T; Yang, JCH; Wu, YL; Kam, TS; Tan, DSW; Yatabe, Y

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br

Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K

Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

Yang, JCH; Ohe, Y; Chiu, CH; Ou, XL; Cantarini, M; Janne, PA; Hartmaier, RJ; Ahn, MJ

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma

Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH

Prognostic value of FOXP3+regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

Hur, JY; Ku, BM; Park, S; Jung, HA; Lee, SH; Ahn, MJ

Metabolic parameters on baseline F-18-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma

Kwon, HR; Cho, JH; Park, S; Lee, SH; Ahn, MJ; Choi, JY; Lee, KH; Jung, HA; Moon, SH

A Response to the Letter to the Editor: Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer

Lee, J; Ahn, MJ

Prognostic Significance of Pseudotime from Texture Parameters of FDG PET/CT in Locally Advanced Non-Small-Cell Lung Cancer with Tri-Modality Therapy

Lee, H; Kim, H; Choi, YS; Pyo, HR; Ahn, MJ; Choi, JY

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Okada, M; Kato, K; Cho, BC; Takahashi, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Matsumura, Y; Takazawa, A; Kitagawa, Y

A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer

Kim, HR; Lee, SJ; Park, S; Jung, HA; Lee, SH; Jeong, HS; Chung, MK; Ahn, MJ

The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer

Kang, N; Kim, KH; Jeong, BH; Lee, K; Kim, H; Kwon, OJ; Ahn, MJ; Cho, J; Lee, HY; Um, SW

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study

Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer

Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH

Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1

Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Demetri, GD; De Braud, F; Drilon, A; Siena, S; Patel, MR; Cho, BC; Liu, SV; Ahn, MJ; Chiu, CH; Lin, JJ; Goto, K; Lee, J; Bazhenova, L; John, T; Fakih, M; Chawla, SP; Dziadziuszko, R; Seto, T; Heinzmann, S; Pitcher, B; Chen, D; Wilson, TR; Rolfo, C

Predictive Value of F-18-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer

Yoo, J; Lee, J; Cheon, M; Woo, SK; Ahn, MJ; Pyo, HR; Choi, YS; Han, JH; Choi, JY

Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer

Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial

Ahn, MJ; Cho, BC; Ou, XL; Walding, A; Dymond, AW; Ren, S; Cantarini, M; Janne, PA

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Passaro, A; Leighl, N; Blackhall, F; Popat, S; Kerr, K; Ahn, MJ; Arcila, ME; Arrieta, O; Planchard, D; de Marinis, F; Dingemans, AM; Dziadziuszko, R; Faivre-Finn, C; Feldman, J; Felip, E; Curigliano, G; Herbst, R; Janne, PA; John, T; Mitsudomi, T; Mok, T; Normanno, N; Paz-Ares, L; Ramalingam, S; Sequist, L; Vansteenkiste, J; Wistuba, II; Wolf, J; Wu, YL; Yang, SR; Yang, JCH; Yatabe, Y; Pentheroudakis, G; Peters, S

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Cho, BC; Han, JY; Kim, SW; Lee, KH; Cho, EK; Lee, YG; Kim, DW; Kim, JH; Lee, GW; Lee, JS; Shim, BY; Kim, JS; Chun, SH; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Lee, Y; Lee, DH; Kang, JA; Lee, N; Kwon, MJ; Espenschied, C; Yablonovitch, A; Ahn, MJ

Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Park, S; Oh, D; Choi, YL; Chi, SA; Kim, K; Ahn, MJ; Sun, JM

Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naive Stage IV Non-Small Cell Lung Cancer Patients

Kim, BG; Jang, JH; Kim, JW; Shin, SH; Jeong, BH; Lee, K; Kim, H; Kwon, OJ; Ahn, MJ; Um, SW

Clinical Value of Surveillance F-18-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy

Lim, CH; Park, SB; Kim, HK; Choi, YS; Kim, J; Ahn, YC; Ahn, MJ; Choi, JY

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

Ku, BM; Kim, YJ; Park, D; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Sun, JM

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

Park, S; Sun, JM; Choi, YL; Oh, D; Kim, HK; Lee, T; Chi, SA; Lee, SH; Choi, YS; Jung, SH; Ahn, MJ; Ahn, YC; Park, K; Shim, YM

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Niu, J; Maurice-Dror, C; Lee, DH; Kim, DW; Nagrial, A; Voskoboynik, M; Chung, HC; Mileham, K; Vaishampayan, U; Rasco, D; Golan, T; Bauer, TM; Jimeno, A; Chung, V; Chartash, E; Lala, M; Chen, Q; Healy, JA; Ahn, MJ

Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer

Ku, BM; Heo, JY; Kim, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke

Kim, HJ; Chung, JW; Bang, OY; Cho, YH; Lim, YJ; Hwang, J; Seo, WK; Kim, GM; Kim, HJ; Ahn, MJ

Encorafenib plus binimetinib in patients with BRAF(V)(600)-mutant non-small cell lung cancer: Phase II PHAROS study design

Riely, GJ; Ahn, MJ; Felip, E; Ramalingam, SS; Smit, EF; Tsao, AS; Alcasid, A; Usari, T; Wissel, PS; Wilner, KD; Johnson, BE

Lung Cancer in Korea

Park, S; Choi, CM; Hwang, SS; Choi, YL; Kim, HY; Kim, YC; Kim, YT; Lee, HY; Song, SY; Ahn, MJ

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Camidge, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Hochmair, MJ; Lee, KH; Delmonte, A; Campelo, DHMRG; Kim, DW; Griesinger, F; Felip, E; Califano, R; Spira, AI; Gettinger, SN; Tiseo, M; Lin, HMM; Liu, YY; Vranceanu, F; Niu, HF; Zhang, PK; Popat, S

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience

Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH

Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)

Kim, H; Kim, DW; Kim, M; Lee, Y; Ahn, HK; Cho, JH; Kim, I; Lee, YG; Shin, SH; Park, SE; Jung, J; Kang, EJ; Ahn, MJ

Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer

Im, Y; Lee, H; Lee, HY; Baek, SY; Jeong, BH; Lee, K; Kim, H; Kwon, OJ; Han, J; Lee, KS; Ahn, MJ; Kim, J; Um, SW

Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma

Kang, EJ; Ahn, MJ; Ock, CY; Lee, KW; Kwon, JH; Yang, Y; Choi, YH; Kim, MK; Ji, JH; Yun, T; Nam, BH; Kim, SB; Keam, B

Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system

Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

Complementary Use of Presepsin with the Sepsis-3 Criteria Improved Identification of High-Risk Patients with Suspected Sepsis

Park, JE; Lee, B; Yoon, SJ; Park, CM; Jung, CW; Ahn, MJ; Park, HD; Hwang, SY; Shin, TG; Kang, ES

Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy

Lee, J; Ahn, MJ

Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

Cho, BC; Yoh, K; Perets, R; Nagrial, A; Spigel, DR; Gutierrez, M; Kim, DW; Kotasek, D; Rasco, D; Niu, JX; Satouchi, M; Ahn, MJ; Lee, DH; Maurice-Dror, C; Siddiqi, S; Ren, YX; Altura, RA; Bar, J

Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer

Park, S; Lee, C; Ku, BM; Kim, M; Park, WY; Kim, NKD; Ahn, MJ

Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model

Koh, J; Kim, S; Lee, SN; Kim, SY; Kim, JE; Lee, KY; Kim, MS; Heo, JY; Park, YM; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Yang, S; Ha, SJ; Lim, YT; Ahn, MJ

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12

Lee, YG; Chang, H; Keam, B; Chun, SH; Park, J; Park, KU; Shin, SH; An, HJ; Lee, KE; Lee, KW; Kim, HR; Kim, SB; Ahn, MJ; Hwang, IG

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)

Garon, EB; Cho, BC; Reinmuth, N; Lee, KH; Luft, A; Ahn, MJ; Robinet, G; Le Moulec, S; Natale, R; Schneider, J; Shepherd, FA; Garassino, MC; Geater, SL; Szekely, ZP; Ngoc, TV; Liu, F; Scheuring, U; Patel, N; Peters, S; Rizvi, NA

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

Paz-Ares¹, L; Barlesi, F; Siena, S; Ahn, MJ; Drilon, A; Conley, A; Rolfo, C; Wolf, J; Seto, T; Doebele, R; Kapre, A; Chen, D; McCallum, S; Osborne, S; Demetri, G

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Passaro¹, A; Mok, T; Peters, S; Popat, S; Ahn, MJ; de Marinis, F

Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma

Keam¹, B; Park, JY; Kim, JP; Kim, GD; Yu, YS; Cho, SH; Kim, S; Ahn, HK; Chun, SH; Kwon, JH; Yun, T; Kim, JW; Kim, JE; Ahn, MJ; Kim, JH; Yun, HJ

High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program

Park¹, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Dziadziuszko¹, R; Krebs, MG; De Braud, F; Siena, S; Drilon, A; Doebele, RC; Patel, MR; Cho, BC; Liu, SV; Ahn, MJ; Chiu, CH; Farago, AF; Lin, CC; Karapetis, CS; Li, YC; Day, Bm; Chen, D; Wilson, TR; Barlesi, F

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer

Lim¹, SH; Sun, JM; Hong, J; Oh, D; Ahn, YC; Chung, MK; Jeong, HS; Son, YI; Ahn, MJ; Baek, CH; Park, K

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

Perets¹, R; Bar, J; Rasco, DW; Ahn, MJ; Yoh, K; Kim, DW; Nagrial, A; Satouchi, M; Lee, DH; Spigel, DR; Kotasek, D; Gutierrez, M; Niu, J; Siddiqi, S; Li, X; Cyrus, J; Chackerian, A; Chain, A; Altura, RA; Cho, BC

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

Lee¹, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI

A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases

Lee¹, J; Ahn, MJ

Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study

Ahn¹, MJ; Chirovsky, D; Kuyas, H; Auclair, V; Abounit, S; Joo, S; Shah, R; Yang, MH

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer

Ku¹, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040

Harrington¹, KJ; Soulieres, D; Le Tourneau, C; Dinis, J; Licitra, LF; Ahn, MJ; Soria, A; Machiels, JPH; Mach, N; Mehra, R; Burtness, B; Ellison, MC; Cheng, JD; Chirovsky, DR; Swaby, RF; Cohen, EEW

Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study

Kim¹, JH; Lee, JW; Park, K; Ahn, MJ; Moon, JW; Ham, SY; Yi, CA

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors

Kim¹, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib

Kim¹, ES; Barlesi, F; Mok, T; Ahn, MJ; Shen, JW; Zhang, PK; Ou, SHI

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

Park¹, JH; You, GL; Ahn, MJ; Kim, SW; Hong, MH; Han, JY; Ock, CY; Lee, JS; Oh, IJ; Lee, SY; Kim, CH; Min, YJ; Choi, YH; Ryu, JS; Park, SH; Ahn, HK; Shim, BY; Lee, KH; Lee, SY; Kim, JS; Yi, J; Choi, SK; An, H; Kang, JH

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?

Lee¹, J; Ahn, MJ

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

Kim¹, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation

Lee¹, J; Choi, JY; Lim, SW; Ahn, MJ; Park, K; Zo, JI; Shim, YM; Oh, D; Sun, JM

Osimertinib in central nervous system progressive EGFR-mutant lung cancer do we need to detect T790M?

Park¹, S; Ahn, MJ

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor AURA3 overall survival analysis

Papadimitrakopoulou¹, VA; Mok, TS; Han, JY; Ahn, MJ; Delmonte, A; Ramalingam, SS; Kim, SW; Shepherd, FA; Laskin, J; He, Y; Akamatsu, H; Theelen, WSME; Su, WC; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Wu, YL

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Lee¹, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

An increase of CD8(+)T cell infiltration following recurrence is a good prognosticator in HNSCC

So¹, YK; Byeon, SJ; Ku, BM; Ko, YH; Ahn, MJ; Son, YI; Chung, MK

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer Second Interim Analysis of the Phase III ALTA-1L Trial

Camidge¹, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Hochmair, MJ; Lee, KH; Delmonte, A; Garcia Campelo, MR; Kim, DW; Griesinger, F; Felip, E; Califano, R; Spira, A; Gettinger, SN; Tiseo, M; Lin, HM; Gupta, N; Hanley, MJ; Ni, QH; Zhang, PK; Popat, S

Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Koh¹, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Park¹, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

Lim¹, SM; Kim, SW; Cho, BC; Kang, JH; Ahn, MJ; Kim, DW; Kim, YC; Lee, JS; Lee, JS; Lee, SY; Park, KU; An, HJ; Cho, EK; Jang, TW; Kim, BS; Kim, JH; Lee, SS; Na, II; Yoo, SS; Lee, KH

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?

Jung¹, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Hong¹, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Park¹, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

Jung¹, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal added value of contrast-enhanced 2D axial T2 FLAIR

Seong¹, M; Park, S; Kim, ST; Park, SG; Kim, YK; Kim, HJ; Ahn, MJ

Molecular Testing in Lung Cancer Still Big Gap in Implementation for Real-World Use

Ahn¹, MJ

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy

Park¹, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck

Kim¹, HR; Kang, HN; Yun, MR; Ju, KY; Choi, JW; Jung, DM; Pyo, KH; Hong, MH; Ahn, MJ; Sun, JM; Kim, HS; Kim, J; Yoo, J; Kim, KR; Koh, YW; Kim, SH; Choi, EC; Yoon, SO; Shim, HS; Paik, S; Kim, TM; Cho, BC

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors

Kim¹, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ

Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)

Jung¹, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

Jung¹, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea

Kim¹, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ

Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations

Kim¹, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

Dingemans¹, AMC; Soo, RA; Jazieh, AR; Rice, SJ; Kim, YT; Teo, LLS; Warren, GW; Xiao, SY; Smit, EF; Aerts, JG; Yoon, SH; Veronesi, G; De Cobelli, F; Ramalingam, SS; Garassino, MC; Wynes, MW; Behera, M; Haanen, J; Lu, S; Peters, S; Ahn, MJ; Scagliotti, GV; Adjei, AA; Belani, CP

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients

Shim¹, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Lee¹, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors Korean cancer study group HN 18-12

Park¹, J; Chun, SH; Lee, YG; Chang, H; Lee, KW; Kim, HR; Shin, SH; An, HJ; Lee, KE; Hwang, IG; Ahn, MJ; Kim, SB; Keam, B

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma

Lee¹, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer

Lee¹, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial

Rizvi¹, NA; Cho, BC; Reinmuth, N; Lee, KH; Luft, A; Ahn, MJ; van den Heuvel, MM; Cobo, M; Vicente, D; Smolin, A; Moiseyenko, V; Antonia, SJ; Le Moulec, S; Robinet, G; Natale, R; Schneider, J; Shepherd, FA; Geater, SL; Garon, EB; Kim, ES; Goldberg, SB; Nakagawa, K; Raja, R; Higgs, BW; Boothman, AM; Zhao, L; Scheuring, U; Stockman, PK; Chand, VK; Peters, S

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping

Hur¹, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Kim¹, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery

Shin¹, S; Kim, HK; Cho, JH; Choi, YS; Kim, K; Kim, J; Zo, JI; Sun, JM; Ahn, MJ; Park, K; Pyo, H; Ahn, YC; Shim, YM

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests

Byeon¹, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Huber¹, RM; Hansen, KH; Rodriguez, LPA; West, HL; Reckamp, KL; Leighl, NB; Tiseo, M; Smit, EF; Kim, DW; Gettinger, SN; Hochmair, MJ; Kim, SW; Langer, CJ; Ahn, MJ; Kim, ES; Kerstein, D; Groen, HJM; Camidge, DR

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Ku¹, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Oxnard¹, GR; Yang, JCH; Yu, H; Kim, SW; Saka, H; Horn, L; Goto, K; Ohe, Y; Mann, H; Thress, KS; Frigault, MM; Vishwanathan, K; Ghiorghiu, D; Ramalingam, SS; Ahn, MJ

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Ahn¹, MJ; Chiu, CH; Cheng, Y; Han, JY; Goldberg, SB; Greystoke, A; Crawford, J; Zhao, YQ; Huang, XN; Johnson, M; Vishwanathan, K; Yates, JWT; Brown, AP; Mendoza-Naranjo, A; Mok, T

PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by loss of CD28 expression and rescued by IL-151

Kim¹, KH; Kim, HK; Kim, HD; Kim, CG; Lee, H; Han, JW; Choi, SJ; Jeong, S; Jeon, M; Kim, H; Koh, J; Ku, BM; Park, SH; Ahn, MJ; Shin, EC

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Huber¹, RM; Hansen, KH; Rodriguez, LPA; West, HL; Reckamp, KL; Leighl, NB; Tiseo, M; Smit, EF; Kim, DW; Gettinger, SN; Hochmair, MJ; Kim, SW; Langer, CJ; Ahn, MJ; Kim, ES; Kerstein, D; Groen, HJM; Camidge, DR

Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology

Shin¹, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

Grunwald¹, V; Chirovsky, D; Cheung, WY; Bertolini, F; Ahn, MJ; Yang, MH; Castro, G; Berrocal, A; Sjoquist, K; Kuyas, H; Auclair, V; Guillaume, X; Joo, S; Shah, R; Harrington, K

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Sequist¹, LV; Han, JY; Ahn, MJ; Cho, BC; Yu, H; Kim, SW; Yang, JCH; Lee, JS; Su, WC; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, RB; Mellemgaard, A; Ottesen, L; Frewer, P; Ou, XL; Oxnard, G

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Tan¹, WL; Chua, KLM; Lin, CC; Lee, VHF; Tho, LM; Chan, AW; Ho, GF; Reungwetwattana, T; Yang, JC; Kim, DW; Soo, RA; Ahn, YC; Onishi, H; Ahn, MJ; Mok, TSK; Tan, DSW; Yang, F

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials

Drilon¹, A; Siena, S; Dziadziuszko, R; Barlesi, F; Krebs, MG; Shaw, AT; de Braud, F; Rolfo, C; Ahn, MJ; Wolf, J; Seto, T; Cho, BC; Patel, MR; Chiu, CH; John, T; Goto, K; Karapetis, CS; Arkenau, HT; Kim, SW; Ohe, Y; Li, YC; Chae, YK; Chung, CH; Otterson, GA; Murakami, H; Lin, CC; Tan, DSW; Prenen, H; Riehl, T; Chow-Maneval, E; Simmons, B; Cui, N; Johnson, A; Eng, S; Wilson, TR; Doebele, RC

PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence

Byeon¹, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Yang¹, JCH; Kim, SW; Kim, DW; Lee, JS; Cho, BC; Ahn, JS; Lee, DH; Kim, TM; Goldman, JW; Natale, RB; Brown, AP; Collins, B; Chmielecki, J; Vishwanathan, K; Mendoza-Naranjo, A; Ahn, MJ

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Cho¹, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma

Lim¹, JH; Choi, JY; Im, Y; Yoo, H; Jhun, BW; Jeong, BH; Park, HY; Lee, K; Kim, H; Kwon, OJ; Han, J; Ahn, MJ; Kim, J; Um, SW

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Shin¹, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY

Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer

Shin¹, S; Choi, YS; Jung, JJ; Im, Y; Shin, SH; Kang, D; Cho, JH; Kim, HK; Kim, J; Zo, JI; Shim, YM; Park, K; Ahn, MJ; Ahn, YC; Lee, G; Cho, J; Lee, HY; Park, HY

Cancer Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms

Bang¹, OY; Chung, JW; Lee, MJ; Seo, WK; Kim, GM; Ahn, MJ

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Kim¹, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

Lee¹, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

Ahn¹, MJ; Han, JY; Kim, DW; Cho, BC; Kang, JH; Kim, SW; Yang, JCH; Mitsudomi, T; Lee, JS

Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review

Lee¹, T; Cho, J; Baek, CH; Son, YI; Jeong, HS; Chung, MK; Hong, SD; Ahn, YC; Oh, DR; Noh, JM; Park, K; Ahn, MJ; Kim, HJ; Kim, YK; Ko, YH

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Ahn¹, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Kato¹, K; Cho, BC; Takahashi, M; Okada, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Kodani, M; Kitagawa, Y

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer

Papadimitrakopoulou¹, VA; Han, JY; Ahn, MJ; Ramalingam, SS; Delmonte, A; Hsia, TC; Laskin, J; Kim, SW; He, Y; Tsai, CM; Hida, T; Maemondo, M; Kato, T; Jenkins, S; Patel, S; Huang, XN; Laus, G; Markovets, A; Thress, KS; Wu, YL; Mok, T

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Antonia¹, SJ; Balmanoukian, A; Brahmer, J; Ou, SHI; Hellmann, MD; Kim, SW; Ahn, MJ; Kim, DW; Gutierrez, M; Liu, SV; Schoffski, P; Jager, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro, L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, PA; Rebelatto, MC; Narwal, R; Liang, MN; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, AK; Khleif, SN; Segal, NH

Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Garon¹, EB; Hellmann, MD; Rizvi, NA; Carcereny, E; Leighl, NB; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Felip, E; Goldman, JW; Scalzo, C; Jensen, E; Kush, DA; Hui, R

Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke: The OASIS-Cancer Study

Bang¹, OY; Chung, JW; Cho, YH; Oh, MJ; Seo, WK; Kim, GM; Ahn, MJ

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing

Kim¹, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Kim¹, MJ; Kim, SM; Jung, HA; Hong, JY; Chang, WJ; Choi, MK; Kim, HS; Sun, JM; Park, K; Ahn, MJ

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Jung¹, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

Park¹, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Kim¹, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma

Park¹, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Cho¹, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer

Moon¹, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018

Remon¹, J; Ahn, MJ; Girard, N; Johnson, M; Kim, DW; Lopes, G; Pillai, RN; Solomon, B; Villacampa, G; Zhou, Q

Histopathologic characteristics of advanced-stage ROS1-rearranged non-small-cell lung cancers

Park¹, E; Choi, YL; Ahn, MJ; Han, J

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Jung¹, KH; LoRusso, P; Burris, H; Gordon, M; Bang, YJ; Hellmann, MD; Cervantes, A; de Olza, MO; Marabelle, A; Hodi, S; Ahn, MJ; Emens, LA; Barlesi, F; Hamid, O; Calvo, E; McDermott, D; Soliman, H; Rhee, I; Lin, R; Pourmohamad, T; Suchomel, J; Tsuhako, A; Morrissey, K; Mahrus, S; Morley, R; Pirzkall, A; Davis, SL

Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer

Bak¹, SH; Park, H; Sohn, I; Lee, SH; Ahn, MJ; Lee, HY

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients

Da Nam¹, B; Kim, TJ; Park, K; Ahn, MJ; Choi, YL; Chung, MJ; Kim, TS; Lee, KS

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

Cho¹, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC

Barlesi¹, F; Garon, EB; Kim, DW; Felip, E; Han, JY; Kim, JH; Ahn, MJ; Fidler, MJ; Gubens, MA; de Castro, G; Surmont, V; Li, Q; Deitz, AC; Lubiniecki, GM; Herbst, RS

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

Park¹, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?

Ahn¹, MJ

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Park¹, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Leigh¹, NB; Hellmann, MD; Hui, RN; Carcereny, E; Felip, E; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Lubiniecki, GM; Zhang, J; Piperdi, B; Garon, EB

Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery

Cho¹, WK; Oh, D; Kim, HK; Ahn, YC; Noh, JM; Shim, YM; Zo, JI; Choi, YS; Sun, JM; Lee, SH; Ahn, MJ; Park, K; Nam, H

The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kim¹, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

Kim¹, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer

Lee¹, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon¹, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Yoo¹, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer

Lee¹, KH; Ahn, YC; Pyo, H; Noh, JM; Park, SG; Kim, TG; Lee, E; Nam, H; Lee, H; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Drilon¹, A; Fu, SQ; Patel, MR; Fakih, M; Wang, D; Olszanski, AJ; Morgensztern, D; Liu, SV; Cho, BC; Bazhenova, L; Rodriguez, CP; Doebele, RC; Wozniak, A; Reckamp, KL; Seery, T; Nikolinakos, P; Hu, ZY; Oliver, JW; Trone, D; McArthur, K; Patel, R; Multani, PS; Ahn, MJ

Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations

Yang¹, B; Lee, H; Um, SW; Kim, K; Zo, JI; Shim, YM; Kwon, OJ; Lee, KS; Ahn, MJ; Kim, H

Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies

Ahn¹, MJ; Tsai, CM; Shepherd, FA; Bazhenova, L; Sequist, LV; Hida, T; Yang, JCH; Ramalingam, SS; Mitsudomi, T; Janne, PA; Mann, H; Cantarini, M; Goss, G

Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer FDG Uptake and Risk Stratification

Moon¹, SH; Sun, JM; Ahn, JS; Park, K; Ahn, MJ; Choi, JY

Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer

Moon¹, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim¹, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Herbst¹, RS; Baas, P; Perez-Gracia, JL; Felip, E; Kim, DW; Han, JY; Molina, JR; Kim, JH; Arvis, CD; Ahn, MJ; Majem, M; Fidler, MJ; Surmont, V; de Castro, G; Garrido, M; Shentu, Y; Emancipator, K; Samkari, A; Jensen, EH; Lubiniecki, GM; Garon, EB

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer

Lim¹, SW; Ahn, MJ

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma

Lim¹, SM; Cho, SH; Hwang, IG; Choi, JW; Chang, H; Ahn, MJ; Park, KU; Kim, JW; Ko, YH; Ahn, HK; Cho, BC; Nam, BH; Chun, SH; Hong, JH; Kwon, JH; Choi, JG; Kang, EJ; Yun, T; Lee, KW; Kim, JH; Kim, JS; Lee, HW; Kim, MK; Jung, D; Kim, JE; Keam, B; Yun, HJ; Kim, S; Kim, HR

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer

Lee¹, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Cohen¹, EEW; Soulieres, D; Le Tourneau, C; Dinis, J; Licitra, L; Ahn, MJ; Soria, A; Machiels, JP; Mach, N; Mehra, R; Burtness, B; Zhang, PY; Cheng, J; Swaby, RF; Harrington, KJ

Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion

Kim¹, H; Oh, D; Ahn, YC; Park, K; Ahn, MJ; Lee, SH; Sun, JM; Shim, YM; Zo, JI; Choi, YS; Kim, HK; Cho, JH

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

Camidge¹, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Lee, JS; Hochmair, MJ; Li, JYC; Chang, GC; Lee, KH; Gridelli, C; Delmonte, A; Campelo, RG; Kim, DW; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Wu¹, YL; Zhang, L; Kim, DW; Liu, XQ; Lee, DH; Yang, JCH; Ahn, MJ; Vansteenkiste, JF; Su, WC; Felip, E; Chia, V; Glaser, S; Pultar, P; Zhao, S; Peng, B; Akimov, M; Tan, DSW

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations

Drilon¹, A; Ou, SHI; Cho, BC; Kim, DW; Lees, J; Lin, JJ; Zhu, VW; Ahns, MJ; Camidge, DR; Nguyen, J; Zhai, DY; Deng, W; Huang, ZD; Rogers, E; Liu, J; Whitten, J; Lim, JK; Stopatschinskaja, S; Hyman, DM; Doebele, RC; Cui, JJ; Shaw, AT

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial

Lim¹, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Wu¹, YL; Ahn, MJ; Garassino, MC; Han, JY; Katakami, N; Kim, HR; Hodge, R; Kaur, P; Brown, AP; Ghiorghiu, D; Papadimitrakopoulou, VA; Mok, TSK

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Camidge¹, DR; Kim, DW; Tiseo, M; Langer, CJ; Ahn, MJ; Shaw, AT; Huber, RM; Hochmair, MJ; Lee, DH; Bazhenova, LA; Gold, KA; Ou, SHI; West, HL; Reichmann, W; Haney, J; Clackson, T; Kerstein, D; Gettinger, SN

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice

Park¹, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

Lee¹, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Tan¹, EH; Lim, WT; Ahn, MJ; Ng, QS; Ahn, JS; Tan, DSW; Sun, JM; Han, M; Payumo, FC; Mckee, K; Yin, W; Credi, M; Agarwal, S; Jac, J; Park, K

Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach

Lee¹, SW; Park, H; Lee, HY; Sohn, I; Lee, SH; Kang, J; Sun, JM; Ahn, MJ

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer

Lee¹, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea

Choi¹, MK; Ahn, JS; Kim, YC; Cho, BC; Oh, IJ; Kim, SW; Lee, JS; Kim, JH; Ahn, MJ; Park, K

Association of Cancer Cell Type and Extracellular Vesicles With Coagulopathy in Patients With Lung Cancer and Stroke

Chung¹, JW; Cho, YH; Ahn, MJ; Lee, MJ; Kim, GM; Chung, CS; Bang, OY

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer

Wu¹, YL; Yang, JCH; Kim, DW; Lu, S; Zhou, JY; Seto, T; Yang, JJ; Yamamoto, N; Ahn, MJ; Takahashi, T; Yamanaka, T; Kemner, A; Roychowdhury, D; Paolini, J; Usari, T; Wilner, KD; Goto, K

Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer

Kim¹, HK; Ahn, MJ

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

Ku¹, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Goss¹, G; Tsai, CM; Shepherd, FA; Ahn, MJ; Bazhenova, L; Crino, L; de Marinis, F; Felip, E; Morabito, A; Hodge, R; Cantarini, M; Johnson, M; Mitsudomi, T; Janne, PA; Yang, JCH

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer

Cho¹, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy

Park¹, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma

Cho¹, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)

Sun¹, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer

Ahn¹, MJ

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Kim¹, HI; Kim, M; Lee, SH; Park, SY; Kim, YN; Kim, H; Jeon, MJ; Kim, TY; Kim, SW; Kim, WB; Kim, SW; Lee, DH; Park, K; Ahn, MJ; Chung, JH; Shong, YK; Kim, WG; Kim, TH

Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?

Ahn¹, MJ

Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

Park¹, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells

Han¹, KY; Kim, KT; Joung, JG; Son, DS; Kim, YJ; Jo, A; Jeon, HJ; Moon, HS; Yoo, CE; Chung, W; Eum, HH; Kim, S; Kim, HK; Lee, JE; Ahn, MJ; Lee, HO; Park, D; Park, WY

Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer

Lee¹, J; Kim, HK; Park, BJ; Cho, JH; Choi, YS; Zo, JI; Shim, YM; Pyo, H; Ahn, YC; Ahn, JS; Ahn, MJ; Park, K; Kim, J

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Mok¹, TSK; Kim, SW; Wu, YL; Nakagawa, K; Yang, JJ; Ahn, MJ; Wang, J; Yang, JCH; Lu, Y; Atagi, S; Ponce, S; Shi, XJ; Rukazenkov, Y; Haddad, V; Thress, KS; Soria, JC

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer

Sun¹, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Lee¹, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Ahn¹, MJ; Kim, DW; Cho, BC; Kim, SW; Lee, JS; Ahn, JS; Kim, TM; Lin, CC; Kim, HR; John, T; Kao, S; Goldman, JW; Su, WC; Natale, R; Rabbie, S; Harrop, B; Overend, P; Yang, ZF; Yang, JCH

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Shin¹, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer

Ku¹, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer

Lee¹, MY; Ku, BM; Kim, HS; Lee, JY; Lim, SH; Sun, JM; Lee, SH; Park, K; Oh, YL; Hong, M; Jeong, HS; Son, YI; Baek, CH; Ahn, MJ

Characteristics and outcomes of ALK plus non-small cell lung cancer patients in Korea

Lim¹, SH; Yoh, KA; Lee, JS; Ahn, MJ; Kim, YJ; Kim, SH; Zhang, J; Patel, D; Swallow, E; Kageleiry, A; Galebach, P; Lee, D; Stein, K; Degun, R; Park, K

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers

Yu¹, HA; Ahn, MJ; Cho, BC; Gerber, DE; Natale, RB; Socinski, MA; Giri, N; Quinn, S; Sbar, E; Zhang, H; Giaccone, G

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience

Park¹, H; Oh, D; Ahn, YC; Pyo, H; Noh, JM; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Kim, HK; Choi, YS; Kim, J; Zo, JI; Shim, YM

Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ

Shin¹, SW; Lee, BS; Yang, K; Amornkitbamrung, L; Jang, MS; Ku, BM; Cho, SW; Lee, JH; Bae, H; Oh, BK; Ahn, MJ; Lim, YT; Um, SH

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Park¹, K; Cho, EK; Bello, M; Ahn, MJ; Thongprasert, S; Song, EK; Soldatenkova, V; Depenbrock, H; Puri, T; Orlando, M

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer

Govindan¹, R; Szczesna, A; Ahn, MJ; Schneider, CP; Mella, PFG; Barlesi, F; Han, BH; Ganea, DE; Von Pawel, J; Vladimirov, V; Fadeeva, N; Lee, KH; Kurata, T; Zhang, L; Tamura, T; Postmus, PE; Jassem, J; O'Byrne, K; Kopit, J; Li, MS; Tschaika, M; Reck, M

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

Kim¹, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

Ku¹, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ

Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With NoneSmall-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry

Soo¹, RA; Kubo, A; Ando, M; Kawaguchi, T; Ahn, MJ; Ou, SHI

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Kim¹, DW; Tiseo, M; Ahn, MJ; Reckamp, KL; Hansen, KH; Kim, SW; Huber, RM; West, HL; Groen, HJM; Hochmair, MJ; Leighl, NB; Gettinger, SN; Langer, CJ; Rodriguez, LGPA; Smit, EF; Kim, ES; Reichmann, W; Haluska, FG; Kerstein, D; Camidge, DR

Scientific Advances in Thoracic Oncology 2016

Soo¹, RA; Stone, ECA; Cummings, KM; Jett, JR; Field, JK; Groen, HJM; Mulshine, JL; Yatabe, Y; Bubendorf, L; Dacic, S; Rami-Porta, R; Detterbeck, FC; Lim, E; Asamura, H; Donington, J; Wakelee, HA; Wu, YL; Higgins, K; Senan, S; Solomon, B; Kim, DW; Johnson, M; Yang, JCH; Sequist, LV; Shaw, AT; Ahn, MJ; Costa, DB; Patel, JD; Horn, L; Gettinger, S; Peters, S; Wynes, MW; Faivre-Finn, C; Rudin, CM; Tsao, A; Baas, P; Kelly, RJ; Leighl, NB; Scagliotti, GV; Gandara, DR; Hirsch, FR; Spigel, DR

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement

Lim¹, SM; Kim, HR; Lee, JS; Lee, KH; Lee, YG; JooMin, Y; Cho, EK; Lee, SS; Kim, BS; Choi, MY; Shim, HS; Chung, JH; La Choi, Y; Lee, MJ; Kim, M; Kim, JH; Ali, SM; Ahn, MJ; Cho, BC

Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma

Kim¹, KW; Kim, HK; Kim, J; Shim, YM; Ahn, MJ; Choi, YL

Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression

Choi¹, JW; Lee, H; Lee, G; Kim, YR; Ahn, MJ; Park, HJ; Eom, K; Kwon, T

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

Lim¹, SH; Shim, YM; Park, SH; Kim, HK; Choi, YS; Ahn, MJ; Park, K; Zo, JI; Sun, JM

EGFR TKI combination with immunotherapy in non-small cell lung cancer

Ahn MJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Yang JC1¹, Ahn MJ1, Kim DW1, Ramalingam SS1, Sequist LV1, Su WC1, Kim SW1, Kim JH1, Planchard D1, Felip E1, Blackhall F1, Haggstrom D1, Yoh K1, Novello S1, Gold K1, Hirashima T1, Lin CC1, Mann H1, Cantarini M1, Ghiorghiu S1, Janne PA1.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Hui R1¹, Garon EB2, Goldman JW2, Leighl NB3, Hellmann MD4, Patnaik A5, Gandhi L6, Eder JP7, Ahn MJ8, Horn L9, Felip E10, Carcereny E11, Rangwala R12, Lubiniecki GM12, Zhang J12, Emancipator K12, Roach C13, Rizvi NA14.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Drilon A1¹, Siena S2,3, Ou SI4, Patel M5, Ahn MJ6, Lee J6, Bauer TM7, Farago AF8, Wheler JJ9, Liu SV10, Doebele R11, Giannetta L2, Cerea G2, Marrapese G2, Schirru M2, Amatu A2, Bencardino K2, Palmeri L2, Sartore-Bianchi A2, Vanzulli A2,3, Cresta S12, Damian S12, Duca M12, Ardini E13, Li G14, Christiansen J14, Kowalski K14, Johnson AD14, Patel R14, Luo D14, Chow-Maneval E14, Hornby Z14, Multani PS14, Shaw AT8, De Braud FG3,12.

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types

Kim JE1¹, Jang JS2, Kim JW3, Sung YL4, Cho CH5, Lee MA6, Kim DJ7, Ahn MJ8, Lee KY9, Sym SJ10, Lim MC11, Jung H12, Cho EK12, Min KW12.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer

Mok TS1¹, Wu Y-L1, Ahn M-J1, Garassino MC1, Kim HR1, Ramalingam SS1, Shepherd FA1, He Y1, Akamatsu H1, Theelen WS1, Lee CK1, Sebastian M1, Templeton A1, Mann H1, Marotti M1, Ghiorghiu S1, Papadimitrakopoulou VA1; AURA3 Investigators.

Osimertinib for the treatment of non-small cell lung cancer

Sun JM1¹, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.

Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature

Kwon AY1¹, Han J2, Chu J1, Choi YS3, Jeong BH4, Ahn MJ5, Ahn YC6.

A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer

Lee JY¹, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

Kim HR1¹, Jang JS2, Sun JM3, Ahn MJ3, Kim DW4, Jung I5, Lee KH6, Kim JH1, Lee DH7, Kim SW, Cho BC1.

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Leighl NB1¹, Rizvi NA2, de Lima LG Jr3, Arpornwirat W4, Rudin CM5, Chiappori AA6, Ahn MJ7, Chow LQ8, Bazhenova L9, Dechaphunkul A10, Sunpaweravong P11, Eaton K12, Chen J13, Medley S13, Poondru S13, Singh M13, Steinberg J13, Juergens RA14, Gadgeel SM15.

Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study

Lee MJ1¹, Chung JW1, Ahn MJ2, Kim S3, Seok JM1, Jang HM1, Kim GM1, Chung CS1, Lee KH1, Bang OY1.

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery

Cho WK1¹, Oh D1, Ahn YC1, Shim YM2, Zo JI2, Sun JM3, Ahn MJ3, Park K3.

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision

Ahn MJ1¹, Sun JM2, Lee SH2, Ahn JS2, Park K2.

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

Hanna NH1¹, Kaiser R2, Sullivan RN3, Aren OR4, Ahn MJ5, Tiangco B6, Voccia I7, Pawel JV8, Kovcin V9, Agulnik J10, Gaschler-Markefski B11, Barrueco J12, Sikken P11, Schloss C12, Kim JH13; LUME-Lung 2 Study group.

Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?

Kim H1¹, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer

Wang L1¹, Wu YL2, Lu S3, Deng L1, Ahn MJ4, Hsu FM5, Iscoe N6,7, Hossain A8, Puri T9, Zhang P10, Orlando M11.

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

Yang Z1¹, Guo Q1, Wang Y1, Chen K1, Zhang L1, Cheng Z1, Xu Y1, Yin X1, Bai Y1, Rabbie S2, Kim DW3, Ahn MJ4, Yang JC5, Zhang X6.

Value of F-18-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence

Moon SH¹, Cho YS, Son YI, Ahn YC, Ahn MJ, Choi JY, Kim BT, Lee KH

The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations

Cha YK1¹, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.

Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer

Choi JW1¹, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.

Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study

Lim SH1¹, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.

Liquid biopsy in non-small cell lung cancer: come of age

¹,Ahn MJ

Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor

Moon SH1¹, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

Ku BM1¹, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

Byeon S1¹, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Crino L1¹, Ahn MJ2, De Marinis F2, Groen HJ2, Wakelee H2, Hida T2, Mok T2, Spigel D2, Felip E2, Nishio M2, Scagliotti G2, Branle F2, Emeremni C2, Quadrigli M2, Zhang J2, Shaw AT2.

Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study

Bang OY1¹,2, Chung JW1,2, Lee MJ1, Kim SJ1, Cho YH2,3, Kim GM1, Chung CS1, Lee KH1, Ahn MJ4, Moon GJ2,3.

Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria

Kim HS1¹, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

Lim SM1¹,2, Kim HR1, Cho EK3, Min YJ4, Ahn JS5, Ahn MJ5, Park K5, Cho BC1, Lee JH6, Jeong HC6, Kim EK6, Kim JH2.

Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease

Kim HK1¹, Cho JH1, Choi YS1, Zo JI1, Shim YM1, Park K2, Ahn MJ2, Ahn YC3, Kim K4, Kim J5.

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Lee JY1¹, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.

Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy

Chang JH1¹,2, Ahn YC1, Park H1, Oh D1, Noh JM1, Sun JM3, Ahn MJ3, Park K3.

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

Kim HS1¹, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

Kang JH1¹, Ahn MJ2, Kim DW3, Cho EK4, Kim JH5, Shin SW6, Wang X7, Kim JS8, Orlando M9, Park K2.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst RS1¹, Baas P2, Kim DW3, Felip E4, Perez-Gracia JL5, Han JY6, Molina J7, Kim JH8, Arvis CD9, Ahn MJ10, Majem M11, Fidler MJ12, de Castro G Jr13, Garrido M14, Lubiniecki GM15, Shentu Y15, Im E15, Dolled-Filhart M15, Garon EB16.

Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation

Kim N1¹,2, Cho A2, Watanabe H3,4, Choi YL2,5, Aziz M6, Kassner M6, Joung JG7, Park AK1,2, Francis JM8, Bae JS7, Ahn SM5, Kim KM5, Park JO9, Park WY2,7, Ahn MJ9, Park K9, Koo J10, Yin HH6, Cho J1,2,7.

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Ku BM1¹, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.

Pembrolizumab for the treatment of non-small cell lung cancer

Lim SH¹, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

Lee JH1¹, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.

Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open Reply

Giovannetti E1¹, Zucali PA2, Rolfo C3, Assaraf YG4, Peters GJ5.

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Lee JY1¹, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.

Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review

Ahn MJ1¹, D'Cruz A2, Vermorken JB3, Chen JP4, Chitapanarux I5, Dang HQ6, Guminski A7, Kannarunimit D8, Lin TY9, Ng WT10, Park KU11, Chan AT12.

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)

Lee JY1¹, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.

Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy

Lim SH1¹, Lee SJ1, Ahn MJ1, Park K1, Sun JM2.

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

Lim SH1¹, Hong M2, Ahn S3, Choi YL3, Kim KM3, Oh D4, Ahn YC4, Jung SH5, Ahn MJ1, Park K1, Zo JI6, Shim YM6, Sun JM7.

Current Status and Challenges of Cancer Clinical Trials in Korea

Shim BY1¹, Park SH2, Lee S3, Kim JS4, Lee KE5, Kang YK6, Ahn MJ2.

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

Huang KK1¹,2, Jang KW3, Kim S4, Kim HS5,6, Kim SM3, Kwon HJ7, Kim HR7, Yun HJ8, Ahn MJ9, Park KU10, Ramnarayanan K2, McPherson JR2,11, Zhang S2, Rhee JK12, Vettore AL2, Das K2, Ishimoto T2, Kim JH5, Koh YW13, Kim SH13, Choi EC13, Teh BT1,2,14, Rozen SG2,11, Kim TM12, Tan P1,2,15, Cho BC5.

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma

Kim HS1¹, Kim SM2, Kim H3, Pyo KH2, Sun JM4, Ahn MJ4, Park K4, Keam B5, Kwon NJ6, Yun HJ7, Kim HG8, Chung IJ9, Lee JS10, Lee KH11, Kim DJ12, Lee CG13, Hur J14, Chung H15, Park JC15, Shin SK15, Lee SK15, Kim HR1, Moon YW1, Lee YC15, Kim JH1, Paik S16,17, Cho BC1.

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

Kim HS1¹, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs

Lee SJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.

Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer

Cho KR1¹, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

Yoshioka H1¹, Azuma K2, Yamamoto N3, Takahashi T4, Nishio M5, Katakami N6, Ahn MJ7, Hirashima T8, Maemondo M9, Kim SW10, Kurosaki M11, Akinaga S11, Park K7, Tsai CM12, Tamura T13, Mitsudomi T14, Nakagawa K15.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Kim ST1¹, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer

Noh JM1¹, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

Park S¹, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ

Volume-Based Assessment With F-18-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer

Hyun SH1¹, Ahn HK2, Ahn MJ3, Ahn YC4, Kim J5, Shim YM5, Choi JY1.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria JC1¹, Wu YL2, Nakagawa K3, Kim SW4, Yang JJ2, Ahn MJ5, Wang J6, Yang JC7, Lu Y8, Atagi S9, Ponce S10, Lee DH4, Liu Y11, Yoh K12, Zhou JY13, Shi X14, Webster A15, Jiang H14, Mok TS16.

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04

Ahn JS1¹, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer

Ji JH1¹, Oh YL2, Hong M2, Yun JW3, Lee HW2, Kim D4, Ji Y4, Kim DH4, Park WY3, Shin HT3, Kim KM2, Ahn MJ5, Park K5, Sun JM5.

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial

Sun JM1¹, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT

Yang JC1¹, Ahn MJ2, Nakagawa K3, Tamura T4, Barraclough H5, Enatsu S6, Cheng R7, Orlando M8.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Costa DB1¹, Shaw AT2, Ou SH2, Solomon BJ2, Riely GJ2, Ahn MJ2, Zhou C2, Shreeve SM2, Selaru P2, Polli A2, Schnell P2, Wilner KD2, Wiltshire R2, Camidge DR2, Crin? L2.

Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy

Moon SH1¹, Choi JY1, Lee HJ1, Son YI2, Baek CH2, Ahn YC3, Ahn MJ4, Park K4, Kim BT1.

A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test

Choi MK1¹, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Lee JY1¹, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.

Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Cha YK1¹, Lee HY2, Ahn MJ3, Choi YL4, Lee JH1, Park K3, Lee KS1.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Blumenschein GR Jr1¹, Smit EF2, Planchard D3, Kim DW4, Cadranel J5, De Pas T6, Dunphy F7, Udud K8, Ahn MJ9, Hanna NH10, Kim JH11, Mazieres J12, Kim SW13, Baas P14, Rappold E15, Redhu S15, Puski A16, Wu FS15, J?nne PA17.

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Garon EB1¹, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.

Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series

Kim SM1¹, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Lee MY1¹, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim DH1, Lee SI1, Park KW1.

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma

Lee MY1¹, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim do H1, Lee SI1, Park KW1.

AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer

Janne PA1¹, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

Lim SH1¹, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.

Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients

Woo HI1¹, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea

Baek JH1¹, Sun JM2, Min YJ3, Cho EK4, Cho BC5, Kim JH5, Ahn MJ2, Park K2.

Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer

Um SW1¹, Kim HK, Jung SH, Han J, Lee KJ, Park HY, Choi YS, Shim YM, Ahn MJ, Park K, Ahn YC, Choi JY, Lee KS, Suh GY, Chung MP, Kwon OJ, Kim J, Kim H.

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Kim HS1¹, Kwon HJ2, Jung I3, Yun MR4, Ahn MJ5, Kang BW6, Sun JM5, Kim SB7, Yoon DH7, Park KU8, Lee SH9, Koh YW10, Kim SH10, Choi EC10, Koo DH11, Sohn JH12, Kim B13, Kwon NJ14, Yun HJ15, Lee MG16, Lee JH17, Kim TM18, Kim HR19, Kim JH19, Paik S20, Cho BC21.

BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

Ku BM1¹, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Sun JM1¹, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial

Park K1¹, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS.

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

Ku BM¹, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ.

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

Yang JC1¹, Kang JH2, Mok T3, Ahn MJ4, Srimuninnimit V5, Lin CC1, Kim DW6, Tsai CM7, Barraclough H8, Altug S9, Orlando M10, Park K11.

Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

Ahn MJ1¹, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM1, Massey D4, Kim M5, Shi Y6, Park K7.

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

Choi MK1¹, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.

Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy

Lee H1¹, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs

Lee JY1¹,?Lim SH,?Kim M,?Kim S,?Jung HA,?Chang WJ,?Choi MK,?Hong JY,?Lee SJ,?Sun JM,?Ahn JS,?Park K,?Ahn MJ.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi F1¹, Scherpereel A, Gorbunova V, Gervais R, Vikstr?m A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin

Chang WJ1¹, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

Lim SH1¹, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.

Prognostic value of volumetric metabolic parameters measured by [F-18]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer

Park¹, SB, Choi, JY, Moon, SH, Yoo, J, Kim, H, Ahn, YC, Ahn, MJ, Park, K, Kim, BT

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer

Lira ME1¹, Choi YL2, Lim SM3, Deng S1, Huang D1, Ozeck M1, Han J4, Jeong JY5, Shim HS5, Cho BC3, Kim J6, Ahn MJ7, Mao M8.

Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy

Chong Y1¹, Kim JH1, Lee HY1, Ahn YC2, Lee KS1, Ahn MJ3, Kim J4, Shim YM4, Han J5, Choi YL5.

When the Abstract Reports a Well-Tolerated Treatment, the Data Should Support It Reply

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma

Sun JM1¹, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.

Assessment of Intratumoral Heterogeneity of Oncogenic Driver Mutations in Surgically-resected Lung Adenocarcinoma: Implications of Percutaneous Biopsy-based Molecular Assay for Target-directed Therapy

Kim HK1¹, Lee HY, Choi YL, Choi SJ, Choi H, Lee J, Han J, Ahn MJ, Lee KS, Kim J.

Volume-based assessment by F-18-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer

Hyun SH1¹, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.

Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients

Kim Y1¹, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy

Ahn JS1¹, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ.

Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma

Lee JY1¹,?Lim SH1,?Lee JY1,?Kim JH1,?Choi KH1,?Park K1,?Sun JM1,?Ahn JS1,?Ahn MJ1.

Health-Related Quality of Life in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)

Rittmeyer A1¹, Gorbunova V, Vikstr?m A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F.

High-throughput Molecular Genotyping for Small Biopsy Samples in Advanced Non-small Cell Lung Cancer Patients

Maeng CH1¹,?Lee HY,?Kim YW,?Choi MK,?Hong JY,?Jung HA,?Lee KS,?Kim H,?Kwon OJ,?Sun JM,?Ahn JS,?Park K,?Um SW,?Ahn MJ.

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)

Barlesi F1¹, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.

Metabolic response evaluated by F-18-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy

Moon SH1¹, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ.

Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-celll lung cancer

Park S1¹, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ.

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

¹,[No authors listed]

Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery

Ahn HK1¹, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Ahn MJ.

Epidermal Growth Factor Receptor Inhibition in Lung Cancer Status 2012

Hirsch FR1¹, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS.

Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute

Han B1¹, Sun JM, Ahn JS, Park K, Ahn MJ.

Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors

Lee SJ1¹, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer

Lira ME1¹, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer

Lee HY1¹, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn MJ.

Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01)

Sun JM1¹, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group.

A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)

Ji JH1; Korean Cancer Study Group (KCSG)¹, Yun T, Kim SB, Kang JH, Park JC, Cho IS, Sohn CH, Heo DS, Jang JS, Shin SW, Hwang DW, Sun JM, Park K, Ahn MJ.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation

Cho SH1¹, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer

Ahn MJ1¹, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.

Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland

Sung JY1¹, Ahn HK, Kwon JE, Jeong H, Baek CH, Son YI, Ahn YC, Park K, Ahn MJ, Ko YH.

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Han JY1¹, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations

Ahn MJ1¹,?Won HH,?Lee J,?Lee ST,?Sun JM,?Park YH,?Ahn JS,?Kwon OJ,?Kim H,?Shim YM,?Kim J,?Kim K,?Kim YH,?Park JY,?Kim JW,?Park K.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

Kim ST1¹, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy

Lee S1¹, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.

Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck

Sun JM1¹, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, Baek JH, Park K, Ahn MJ.

Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats

Sun JM1¹, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ.

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

Sun JM1¹, Han J, Ahn JS, Park K, Ahn MJ.

New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy

Lee HY1¹,?Lee KS,?Ahn MJ,?Hwang HS,?Lee JW,?Park K,?Ahn JS,?Kim TS,?Yi CA,?Chung MJ.

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia

Chang JW1¹, Thongprasert S, Wright E, Tsang K, Kim HT, Ahn MJ, Kim JH, Kang JH, Kim SW, Walzer S.

Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan

Ahn MJ1¹, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes

Chang GC1¹, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

Sun JM1¹, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.

Clinical Impact of Amphiregulin Expression in Patients With Epidermal Growth Factor Receptor (EGFR) Wild-Type Nonsmall Cell Lung Cancer Treated With EGFR-Tyrosine Kinase Inhibitors

Chang MH1¹, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.

Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment

Kim ST1¹, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ.

Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy

Sun JM1¹, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ.

Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era

Ahn MJ1¹,?Lee J,?Park YH,?Ahn JS,?Ziogas A,?Zell JA,?Park K,?Ou SH.

Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Sun JM1¹, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K.

Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy

Kim ST1¹, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases

Kim KH1¹,?Lee J,?Lee JI,?Nam do H,?Kong DS,?Ahn YC,?Park HC,?Kwon OJ,?Kim H,?Chang MH,?Yi SY,?Ji SH,?Park YH,?Ahn JS,?Park K,?Ahn MJ.

Clinical Impact of Phosphorylated Signal Transducer and Activator of Transcription 3, Epidermal Growth Factor Receptor, p53, and Vascular Endothelial Growth Factor Receptor I Expression in Resected Adenocarcinoma of Lung by Using Tissue Microarray

Kim HS1¹, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ.

Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer

Lee DH1¹, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH.

Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer

Chang MH1¹,?Lee J,?Han J,?Park YH,?Ahn JS,?Park K,?Ahn MJ.

The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma

Hong JY1¹, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.

House Dust Mite Allergen Der f 2-induced Phospholipase D1 Activation Is Critical for the Production of Interleukin-13 through Activating Transcription Factor-2 Activation in Human Bronchial Epithelial Cells

Park SY1¹, Cho JH, Oh DY, Park JW, Ahn MJ, Han JS, Oh JW.

Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer

Park S1¹, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Janne PA, Ahn MJ.

Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung

Kim Y1¹, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ.

Prognostic Model to Predict Outcomes in Nonsmall Cell Lung Cancer Patients Treated With Gefitinib as a Salvage Treatment

Park MJ1¹,?Lee J,?Hong JY,?Choi MK,?Yi JH,?Lee SJ,?Oh SJ,?Ahn JS,?Park K,?Ahn MJ.

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

Kim HS1¹, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ.

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

Hwang IG1¹, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer

Ahn MJ1¹, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Janne PA, Park K.

Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray

Choi JH1¹, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY, Kim IS.